Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Chalmers (Dundee, United Kingdom), B. Thompson (Owings Mills, MD , United States of America), J. Froehlich (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), J. Dahms (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), I. Gonda (Hayward, CA, United States of America). Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA). 2675

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Early re-colonization with pseudomonas aeruginosa (PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Serial measures of airway function in infants & preschoolers with cystic fibrosis (CF) according to pseudomonas aeruginosa (PsA) status Source: Eur Respir J 2007; 30: Suppl. 51, 449s Year: 2007 Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE) Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 Lung function, symptoms and inflammatory biomarkers in patients with bronchiectasis (brx) with and without chronic pseudomonas aeruginosa (psa) colonisation Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009 Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study Source: Eur Respir J 2009; 34: 1072-1078 Year: 2009 Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to Pseudomonas aeruginosa: resistance to common antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 540s Year: 2001 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001 Impact of Pseudomonas aeruginosa on exacerbation and death in patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – Airway infection in COPD Year: 2019 Pseudomonas aeruginosa infections Source: Respipedia Article Year: 2018 Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD) Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007 Pseudomonas aeruginosa (Pa) antibiotic resistance (AR): Comparison in adults and children with cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020